Document is current
Any future updates will be listed below
-
Authors
Palfi, Stefanie
Peres, Lauren C. https://orcid.org/0000-0002-6620-8600
Koelmeyer, Himara
Alsina, Melissa
Baz, Rachid C.
Blue, Brandon J. https://orcid.org/0000-0003-0639-3768
Corallo, Salvatore
De Avila, Gabriel
Freeman, Ciara
Gonzalez, Rebecca https://orcid.org/0000-0003-0024-0699
Grajales-Cruz, Ariel
Harvey, Kristy
Liu, Hien D.
Nishihori, Taiga https://orcid.org/0000-0002-2621-7924
Oliveira, Guilherme H.
Oswald, Laura B.
Castaneda Puglianini, Omar https://orcid.org/0000-0003-0423-5870
Selvakumar, Sruthi
Sharma, Alexis Behne
Wang, Elicia
Shain, Kenneth H.
Jain, Michael https://orcid.org/0000-0002-7789-1257
Locke, Frederick L.
Alomar, Mohammed
Hansen, Doris K. https://orcid.org/0000-0002-9813-3578
Lee, Dae Hyun https://orcid.org/0000-0001-8141-0404
-
Funding
Funding for this research was provided by:
American Heart Association (24CDA1271837)
Florida Department of Health (MOABE)
- License Information
-
More Information
Article History
Received: 17 December 2024
Revised: 2 March 2025
Accepted: 19 March 2025
First Online: 14 April 2025
Competing interests
: F.L.L.: Scientific advisory role for A2, Allogene, Amgen, Bluebird Bio, BMS/Celgene, Calibr, Caribou, Cellular Biomedicine group, Daiichi Sankyo, GammaDelta Therapeutics, Iovance, Kite Pharma, Janssen, Legend Biotech, Novartis, Sana, Takeda, Wugen, Umoja. Research Funding from: Kite Pharma (institutional), Allogene (institutional), CERo Therapeutics (institutional), Novartis (institutional), BlueBird Bio (Institutional), BMS (Institutional), National Cancer Institute, Leukemia and Lymphoma Society. Consulting Role for: Cowen, EcoR1, Emerging Therapy Solutions, Gerson Lehrman Group (GLG). M.J.: Consulting Advisory for: Kite/ Gilead, Novartis, BMS, Myeloid Tx; Research Funding: Incyte, Kite/ Gilead. K.H.S.: Consultancy and advisory board for Sanofi, Bristol Myers Squibb (BMS), Janssen, Amgen, Karyopharm, Adaptive, GSK and Takeda; Research support with Karyopharm and Abbvie. L.C.P.: Research support from Bristol Myers Squibb, Karyopharm and Janssen. Research support from NCI and DoD. A.G.-C.: Advisory board and speaking bureau of Sanofi. R.C.B: Research support from BMS, Karyopharm, Abbvie, Janssen. Advisory board member from Janssen, Pfizer, GSK, BMS, Abbvie, Takeda, Sanofi. D.K.H. is supported by the NCI (R01CA281756-01A1) and the Pentecost Family Myeloma Research Center. Research funding from Bristol-Myers Squibb, Janssen, Karyopharm, Kite Pharma, and Adaptive Biotech; Consulting or advisory role for Bristol Myers Squibb, Janssen, Legend Biotech, Pfizer, Kite Pharma, AstraZeneca, and Karyopharm. D.H.L. is supported by AHA Career Development Award (24CDA1271837), Florida Department of Health Casey DeSantis Cancer Innovation Fund (ID# MOABE). Consultant fee from Lexicon Pharmaceuticals. O.C.P.: Consultant Fee from Legend Biotech USA Inc; Bristol Myer Squibb, and Janssen Biotech Inc. A.M.: Advisory for BMS, Janssen, Sanofi. Research Support for BMS, Janssen, Pfizer. T.N.: Clinical trial support to the institution by Novartis, Clinical trial support (drug only supply) to the institution by Karyopharm, Consultant to Alexion. The remaining authors have no competing risks to disclose.
